Hyphens Pharma licenses Wynzora Cream for ASEAN countries from MC2 Therapeutics
MC2 Therapeutics to Present at Upcoming Conferences Copenhagen, February 26th, 2024 MC2 Therapeutics, a commercial stage biotech company focused on developing novel treatment paradigms within...
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial MC2-25 CKD is a first-in-class drug candidate and a potential breakthrough in the...
MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus MC2-25 VLS is a first-in-class drug candidate for urea associated skin...
MC2-32 (RGRN-305) a first in class, oral therapy targeting multiple pathways involved in Hidradenitis Suppurativa (HS) achieves highly positive data in randomized, double-blinded, placebo-controlled...
MC2 Therapeutics’ drug candidate for hidradenitis suppurativa has shown hints of efficacy potential in a Phase IIa trial, sparking plans for Phase IIb development with a primary endpoint that may be a higher bar than previous approvals.
DURHAM, N.C. and COPENHAGEN, Denmark, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), EPI Health, a Novan Company, and MC2 Therapeutics today announced that data from a 17-question survey sponsored by the Company was published in a poster entitled, “Improving Patient Acceptability and Adherence in Psoriasis Treatment,” at the 42nd Annual Fall Clinical Dermatology Conference® taking place October 20-23, 2022, in Las Vegas, NV.
MC2 Therapeutics has dosed the first subjects in a Phase II clinical trial of its drug candidate, MC2-25 Cream, for the treatment of moderate to severe chronic kidney disease-associated pruritus (CKD-aP) in stage 3-5 CKD patients.
DURHAM, N.C. and COPENHAGEN, Denmark, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that EPI Health, a Novan Company, and MC2 Therapeutics presented data from a previously unpublished subgroup analysis of the U.S. Phase 3 pivotal study of WYNZORA® Cream at the Skin of Color Update 2022 Conference held September 9-11, 2022, in New York, NY.
COPENHAGEN, Denmark, Sept. 14, 2022 /PRNewswire/ -- MC2 Therapeutics A/S, a commercial stage pharmaceutical company, engaged in research in skin biology and development of novel treatment paradigms for autoimmune and chronic inflammatory skin conditions, announces that the first patients have been dosed in its European Phase 2 trial, MC2-25-C1, evaluating the safety and efficacy of MC2-25 Cream compared to MC2-25 vehicle in treating moderate to severe CKD-aP in patients with CKD stages 3-5.